Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGTNASDAQ:DYNNASDAQ:GPCRNASDAQ:HROW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$7.24-0.3%$5.58$3.72▼$12.61$826.60M1.821.31 million shs3.12 million shsDYNDyne Therapeutics$10.63+4.6%$11.71$6.36▼$47.45$1.15B1.161.75 million shs1.42 million shsGPCRStructure Therapeutics$22.38+1.3%$23.39$13.22▼$47.48$1.27B-1.87852,646 shs1.06 million shsHROWHarrow$31.71+2.3%$27.17$20.36▼$59.23$1.14B0.4495,618 shs357,552 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-0.28%-4.99%+50.21%+11.90%-18.56%DYNDyne Therapeutics+4.63%-2.12%-9.07%-5.60%-70.17%GPCRStructure Therapeutics+1.27%+6.72%-8.84%+11.90%-48.76%HROWHarrow+2.29%+4.27%+22.43%+14.68%+47.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGTCogent Biosciences1.747 of 5 stars3.43.00.00.01.20.00.6DYNDyne Therapeutics2.776 of 5 stars4.50.00.00.02.33.30.0GPCRStructure Therapeutics2.289 of 5 stars3.52.00.00.01.91.70.6HROWHarrow2.2847 of 5 stars3.51.00.00.02.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.75Moderate Buy$14.57101.26% UpsideDYNDyne Therapeutics 2.94Moderate Buy$41.87293.85% UpsideGPCRStructure Therapeutics 3.00Buy$76.17240.33% UpsideHROWHarrow 3.00Buy$61.4093.63% UpsideCurrent Analyst Ratings BreakdownLatest HROW, GPCR, DYN, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025DYNDyne TherapeuticsSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$13.006/23/2025GPCRStructure TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$65.006/23/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$89.006/18/2025DYNDyne TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/18/2025DYNDyne TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $32.006/17/2025COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/17/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/12/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.006/11/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$37.006/10/2025HROWHarrowWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform6/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/ADYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$15.10 per shareN/AHROWHarrow$199.61M5.83$0.14 per share226.71$1.95 per share16.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$255.86M-$1.84N/AN/AN/AN/A-149.79%-75.61%8/5/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.59N/AN/AN/AN/A-52.83%-48.84%8/11/2025 (Estimated)GPCRStructure Therapeutics-$122.53M-$0.87N/AN/AN/AN/A-16.35%-15.71%8/6/2025 (Estimated)HROWHarrow-$17.48M-$0.56N/A79.28N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)Latest HROW, GPCR, DYN, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/A5/8/2025Q1 2025HROWHarrow$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million5/6/2025Q1 2025COGTCogent Biosciences-$0.56-$0.52+$0.04-$0.52N/AN/A3/27/2025Q4 2024HROWHarrow$0.11$0.25+$0.14$0.24$66.01 million$66.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A5.135.13DYNDyne TherapeuticsN/A20.3520.35GPCRStructure TherapeuticsN/A23.2923.29HROWHarrow2.010.910.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/ADYNDyne Therapeutics96.68%GPCRStructure Therapeutics91.78%HROWHarrow72.76%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences7.29%DYNDyne Therapeutics20.77%GPCRStructure Therapeutics9.43%HROWHarrow13.67%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableDYNDyne Therapeutics100113.67 million90.06 millionOptionableGPCRStructure Therapeutics13657.34 million51.94 millionOptionableHROWHarrow18236.69 million31.67 millionOptionableHROW, GPCR, DYN, and COGT HeadlinesRecent News About These CompaniesWoodmont Investment Counsel LLC Buys 22,293 Shares of Harrow, Inc. (NASDAQ:HROW)June 21, 2025 | marketbeat.comHarrow Shows Market Leadership With Jump To 83 RS RatingJune 20, 2025 | msn.comAssenagon Asset Management S.A. Sells 99,446 Shares of Harrow, Inc. (NASDAQ:HROW)June 20, 2025 | marketbeat.comHarrow Appoints Mike Biega as Vice President of Investor Relations and CommunicationsJune 19, 2025 | finance.yahoo.comHarrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of "Buy" from AnalystsJune 17, 2025 | americanbankingnews.comI Am Swimming In Dividends With +7% YieldsJune 13, 2025 | seekingalpha.comHarrow, Inc. (NASDAQ:HROW) Given Consensus Recommendation of "Buy" by BrokeragesJune 12, 2025 | marketbeat.comHarrow (NASDAQ:HROW) Now Covered by Analysts at BTIG ResearchJune 12, 2025 | marketbeat.comWhat is William Blair's Estimate for Harrow Q2 Earnings?June 12, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Harrow (HROW) with Outperform RecommendationJune 12, 2025 | msn.comHarrow wins new Outperform at William Blair after licensing deal for pain drugJune 10, 2025 | msn.comHarrow (NASDAQ:HROW) Shares Gap Up - Still a Buy?June 10, 2025 | marketbeat.comHarrow (NASDAQ:HROW) Coverage Initiated at William BlairJune 10, 2025 | marketbeat.comHarrow acquires U.S. commercial rights to BYQLOVI from Formosa PharmaceuticalsJune 10, 2025 | msn.comHarrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa PharmaceuticalsJune 9, 2025 | prnewswire.comHarrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa PharmaceuticalsJune 9, 2025 | businesswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 29,262 Shares of Harrow, Inc. (NASDAQ:HROW)June 8, 2025 | marketbeat.comHarrow (NASDAQ:HROW) Trading Down 4.7% - Here's WhyJune 5, 2025 | marketbeat.comWellington Management Group LLP Sells 11,951 Shares of Harrow, Inc. (NASDAQ:HROW)June 5, 2025 | marketbeat.comBank of America Corp DE Trims Stock Holdings in Harrow, Inc. (NASDAQ:HROW)June 5, 2025 | marketbeat.comNuveen Asset Management LLC Decreases Holdings in Harrow, Inc. (NASDAQ:HROW)June 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeJoby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsBy Jeffrey Neal Johnson | June 4, 2025View Joby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsSteel Dynamics Shares Climb After Tariff AnnouncementBy Dan Schmidt | June 3, 2025View Steel Dynamics Shares Climb After Tariff AnnouncementHROW, GPCR, DYN, and COGT Company DescriptionsCogent Biosciences NASDAQ:COGT$7.24 -0.02 (-0.28%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$7.24 0.00 (0.00%) As of 06/24/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Dyne Therapeutics NASDAQ:DYN$10.63 +0.47 (+4.63%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$10.48 -0.15 (-1.41%) As of 06/24/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Structure Therapeutics NASDAQ:GPCR$22.38 +0.28 (+1.27%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$22.49 +0.11 (+0.49%) As of 06/24/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Harrow NASDAQ:HROW$31.71 +0.71 (+2.29%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$31.73 +0.02 (+0.06%) As of 06/24/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
